PSA Test Valuable In Predicting Biopsy Need

A new Mayo Clinic study found the prostate-specific antigen test was accurate in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a news release said.

Advertisement

More than 600 men between the ages of 40 and 79 were prospectively followed since 1990. The study found men in their 40s and 50s with a baseline PSA at or above the median were much more likely to both undergo a biopsy and be diagnosed with low-risk prostate cancer.

Related Articles about Prostate Cancer:
Physicians Question Federal Panel’s Recommendation on Prostate Screening Tests
Vitamin E Linked to Higher Risk of Prostate Cancer
Tool Determines Risk of Death of Prostate Cancer Patients After Radiation

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.